CTYPE html> BacVacDB | Details of Bacterial Vaccine

Details of Bacterial Vaccine

This bacterial vaccine card gives comprehensive information about each vaccine.
Detailed Information
ID1124
Name of the vaccineMenactra
MicrobeBacteria
Disease nameMeningococcal disease
Name of bacteriaNeisseria meningitidis
Type of vaccineInactivated
Nucleic acid contentDNA
Age9 months to 55 years
Description of the vaccineMeningococcal (Groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine.
Name of the manufacturerSanofi Pasteur Inc.
Name of the manufacturing countryUnited States
Year of manufacture2005
Clinical Phase statusApproved
Bacterial strainGram-negative diplococcus.
EfficacyWas inferred from the immunologic equivalence to Menomune – A/C/Y/W-135 vaccine as assessed by SBA.
Vaccine formulationSolution supplied in 0.5 mL single-dose vials.
DosagePrimary Vaccination: Children 9 to 23 months : Two doses, three months apart. Individuals 2 to 55 years: A single dose. Booster Vaccination: Individuals 15 to 55 years : single booster dose for those at continued risk for meningococcal disease, after 4 years have elapsed.
Mechanism of actionProduction of bactericidal antibodies specific to the capsular polysaccharides of serogroups A, C, Y and W-135.
Route of administrationIntramuscular
IndicationsTo prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. It does not prevent N meningitidis serogroup B disease.
ExportNA
ApprovalUS FDA
AdjuvantNA
RepurposingNA
Side effects of vaccineInfants and toddlers 9 and 12 months : injection site tenderness, erythema, swelling, irritability, abnormal crying, drowsiness, appetite loss, vomiting, and fever. Individuals 2 -55 years : injection site pain, redness, induration, swelling, anorexia, diarrhoea, irritability, headache, fatigue, malaise and arthralgia.
Post vaccinationNA
Dose typeBoth
Interspecies transferNA
PubMed identifierNA
Clinical trial numberNA
Referencehttps://www.fda.gov/media/75619/download
Other nameNA
Additional LinksNA